|
|
|
|
|
|
|
17.05.25 - 02:54
|
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors (Business Wire)
|
|
|
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025.
Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where he focused on the firm's life sciences practice, and a managing partner at Vivo Ventures where he led numerous investments in China. He was also the president of Anesiva, Inc., a biopharmaceutical company focused on pain-management treatments. Earlier in his career, he held senio...
|
|
|
|
|
|
|
15.05.25 - 14:39
|
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress (Business Wire)
|
|
|
Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide
Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives
Atara has entered into an underwriting agreement for an offering with expected gross proceeds of $16 million that Atara believes is sufficient to fund the ongoing activities required to achieve potential BLA approval
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2025 and business updates.
“We are pleased that we have secured additional financing that is expected to exte...
|
|
|
15.05.25 - 14:33
|
Atara Biotherapeutics Announces Pricing of $16 Million Offering (Business Wire)
|
|
|
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6099 per pre-funded warrant share in an underwritten registered direct offering to a limited number of existing institutional investors, including entities affiliated with Adiumentum Capital Management, EcoR1 Capital, Panacea Venture and Redmile Group. The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable upon issuance. The offering is expected to close on or about May 16, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds from ...
|
|
|
22.04.25 - 16:03
|
Secretome Therapeutics Appoints Dr. Marshelle Smith Warren as Chief Medical Officer (Business Wire)
|
|
|
DALLAS--(BUSINESS WIRE)--#BiotechLeadership--Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, MD, as Chief Medical Officer. Dr. Warren is a highly experienced pharmaceutical executive with over two decades of leadership in clinical development, translational medicine, and regulatory strategy across multiple therapeutic areas, including cell therapy, immunology, cardiovascular, and rare diseases.
Dr. Warren most recently served as Chief Medical Officer at SQZ Biotechnologies, where she led the successful development of first-in-human cell therapy programs, culminating in its acquisition by STEMCELL Technologies in 2024. Previously, she held senior clinical development roles at Atara Biotherapeutics, guiding strategy for allogeneic T-cell therapies, and at industry leaders Gilead Sciences and Amgen. Dr. Warren has directly overseen the submission and execution...
|
|
|
|
|
|
|
07.03.25 - 22:06
|
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress (Business Wire)
|
|
|
Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO™ BLA resubmission in the U.S.
Atara remains focused on delivering on the future financial value of EBVALLO and has paused ATA3219 and ATA3431 CAR-T programs and implemented a workforce reduction of approximately 50% to preserve resources
Strategic review by financial advisor ongoing
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--$ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2024, business updates, and key upcoming milestones for 2025.
“We will further narrow our focus on the future financial value of EBVALLO for the benefit of all stakeholders. Atara continues to productively engage with our partner Pierre Fabre Laboratories and the FDA to help...
|
|
|
|
|
|
|
|
|
|
|
07.02.25 - 22:03
|
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--$ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 1,350 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of February 3, 2025, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to t...
|
|
|
|
|
|
|
|
|
16.01.25 - 15:27
|
XFRA : AT20: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
ATARA BIOTH. NEW DL-,0001 AT20 US0465132068
AB/FROM ONWARDS 16.01.2025 15:14 CET...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
